Identification of a novel DNA aptamer that selectively targets lung cancer serum

Zhao, Yunwang; He, Lei; Huang, Baihai; Zhang, Weidong; Hu, Ailing; Li, Baolin; Liao, Shiqi; Wang, Na

doi:10.1039/d1ra06233f

Cited by 8 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different from secretome SELEX, serum-SELEX needs to link serum proteins to a carboxylate-modified magnetic bead for the separation of unbound sequences. In the report of Zhao et al, CLEC3B was identified as the target protein by MALDI-TOF MS and secondary peptide sequencing MS analysis [ 118 ]. In addition, the ELISA confirmed the overexpression of CLEC3B in lung cancer patients, which makes it useful in the diagnosis [ 119 ].…”

Section: The Application Of Aptamer-based Biomarker Discovery In Vari...mentioning

confidence: 99%

The application of Aptamer in biomarker discovery

Tam

et al. 2023

Biomark Res

View full text Add to dashboard Cite

Biomarkers are detectable molecules that can reflect specific physiological states of cells, organs, and organisms and therefore be regarded as indicators for specific diseases. And the discovery of biomarkers plays an essential role in cancer management from the initial diagnosis to the final treatment regime. Practically, reliable clinical biomarkers are still limited, restricted by the suboptimal methods in biomarker discovery. Nucleic acid aptamers nowadays could be used as a powerful tool in the discovery of protein biomarkers. Nucleic acid aptamers are single-strand oligonucleotides that can specifically bind to various targets with high affinity. As artificial ssDNA or RNA, aptamers possess unique advantages compared to conventional antibodies. They can be flexible in design, low immunogenicity, relative chemical/thermos stability, as well as modifying convenience. Several SELEX (Systematic Evolution of Ligands by Exponential Enrichment) based methods have been generated recently to construct aptamers for discovering new biomarkers in different cell locations. Secretome SELEX-based aptamers selection can facilitate the identification of secreted protein biomarkers. The aptamers developed by cell-SELEX can be used to unveil those biomarkers presented on the cell surface. The aptamers from tissue-SELEX could target intracellular biomarkers. And as a multiplexed protein biomarker detection technology, aptamer-based SOMAScan can analyze thousands of proteins in a single run. In this review, we will introduce the principle and workflow of variations of SELEX-based methods, including secretome SELEX, ADAPT, Cell-SELEX and tissue SELEX. Another powerful proteome analyzing tool, SOMAScan, will also be covered. In the second half of this review, how these methods accelerate biomarker discovery in various diseases, including cardiovascular diseases, cancer and neurodegenerative diseases, will be discussed.

show abstract

Section: The Application Of Aptamer-based Biomarker Discovery In Vari...mentioning

confidence: 99%

The application of Aptamer in biomarker discovery

Tam

et al. 2023

Biomark Res

View full text Add to dashboard Cite

show abstract

“…Thus, aptamers with improved specificity and selectivity can be obtained for diagnostic application. For example, Apt-5 can bind to human CLEC3b, which plays an important role in infection, inflammation, and tumor immunity [73,74]. Aptamer Apt-5 can be used as a molecular probe to detect lung cancer.…”

Section: Serum-selexmentioning

confidence: 99%

Aptamer Development for Cancer Diagnostic

Nordin¹,

Ming²,

Teo³

et al. 2023

Rapid Antigen Testing

View full text Add to dashboard Cite

Early diagnosis improves the prognosis for cancer patients by allowing early intervention to slow or prevent cancer development and lethality. Aptamers are short single-stranded oligonucleotides that have a length of about 25-80 bases. They are produced chemically and extracted using the systematic evolution of ligands by exponential enrichment (SELEX). The use of aptamers as diagnostic tools in cancer is highly recommended due to their ability to recognize various cancer-related molecules and biomarkers with high affinity and specificity. Despite the clear advantages of aptamers, the potential of aptamers in cancer diagnosis is yet to be reached. This chapter will present the best available knowledge on using aptamers as the biorecognition element in the development of cancer biosensor. We will first present the advantages of aptamers in cancer diagnosis as well as various types of SELEX methods with emphasis on clinically relevant samples such as serum, whole cells, and tissue slices. We will also cover the various aptamer detection platforms such as colorimetric, fluorescence and electrochemical platforms. Furthermore, the updates on aptamers specific to KRAS mutation detection in cancer will be reviewed. Finally, the future direction of aptamers in cancer diagnosis will also be discussed.

show abstract

“…Aptamers (single-stranded DNA or RNA) have been proven to be a powerful tool for biomarker discovery. Several researchers have employed aptamers to discover biomarkers in various diseases such as lung cancer [8], leukemias [9], ovarian cancer [10,11], and Chagas disease [12], among many others. However, it is evident that the SELEX strategies utilized in these studies exhibit notable diversity, highlighting the absence of a standardized protocol for biomarker discovery from biological samples.…”

Section: Introductionmentioning

confidence: 99%

Bio-SELEX: A Strategy for Biomarkers Isolation Directly from Biological Samples

Ospina-Villa,

Restrepo-Cano,

Sánchez-Jiménez

2023

MPs

View full text Add to dashboard Cite

Bio-SELEX is a revolutionary method for the discovery of novel biomarkers within biological samples, offering profound insights into diagnosing both infectious and non-infectious diseases. This innovative strategy involves three crucial steps: Traditional SELEX, Pull Down, and mass spectrometry. Firstly, Traditional SELEX involves the systematic selection of specific nucleic acid sequences (aptamers) that bind to the target molecules of interest. These aptamers are generated through iterative rounds of selection, amplification, and enrichment, ultimately yielding highly selective ligands. Secondly, the Pull-Down phase employs these aptamers to capture and isolate the target biomarkers from complex biological samples. This step ensures the specificity of the selected aptamers in binding to their intended targets. Lastly, mass spectrometry is utilized to identify and quantify the captured biomarkers, providing precise information about their presence and concentration in the sample. These quantitative data are invaluable in disease diagnosis and monitoring. Bio-SELEX’s significance lies in its ability to discover biomarkers for a wide range of diseases, spanning infectious and non-infectious conditions. This approach holds great promise for early disease detection, personalized medicine, and the development of targeted therapies. By harnessing the power of aptamers and mass spectrometry, Bio-SELEX advances our understanding of disease biology and opens new avenues for improved healthcare.

show abstract

Identification of a novel DNA aptamer that selectively targets lung cancer serum

Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide.

Cited by 8 publications

References 32 publications

The application of Aptamer in biomarker discovery

The application of Aptamer in biomarker discovery

Aptamer Development for Cancer Diagnostic

Bio-SELEX: A Strategy for Biomarkers Isolation Directly from Biological Samples

Contact Info

Product

Resources

About